Giuseppe Battaglia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1231019/publications.pdf

Version: 2024-02-01

181 papers	9,150 citations	30070 54 h-index	51608 86 g-index
185 all docs	185 docs citations	185 times ranked	10274 citing authors

#	Article	IF	Citations
1	A Progressive Build-up of Perineuronal Nets in the Somatosensory Cortex Is Associated with the Development of Chronic Pain in Mice. Journal of Neuroscience, 2022, 42, 3037-3048.	3.6	8
2	Analgesic Activity of Cinnabarinic Acid in Models of Inflammatory and Neuropathic Pain. Frontiers in Molecular Neuroscience, 2022, 15, .	2.9	2
3	Perineuronal nets are under the control of type-5 metabotropic glutamate receptors in the developing somatosensory cortex. Translational Psychiatry, 2021, 11, 109.	4.8	5
4	Developmental up-regulation of NMDA receptors in the prefrontal cortex and hippocampus of mGlu5 receptor knock-out mice. Molecular Brain, 2021, 14, 77.	2.6	1
5	Genetic Deletion of mGlu3 Metabotropic Glutamate Receptors Amplifies Ischemic Brain Damage and Associated Neuroinflammation in Mice. Frontiers in Neurology, 2021, 12, 668877.	2.4	5
6	Behavioural and biochemical responses to methamphetamine are differentially regulated by mGlu2 and mGlu3 metabotropic glutamate receptors in male mice. Neuropharmacology, 2021, 196, 108692.	4.1	8
7	Repeated episodes of transient reduction of oxygen exposure simulating aircraft cabin conditions enhance resilience to stress in mice. European Journal of Neuroscience, 2021, 54, 7109-7124.	2.6	0
8	Upregulation of Tolerogenic Pathways by the Hydrogen Sulfide Donor GYY4137 and Impaired Expression of H2S-Producing Enzymes in Multiple Sclerosis. Antioxidants, 2020, 9, 608.	5.1	9
9	Maternal stress programs accelerated aging of the basal ganglia motor system in offspring. Neurobiology of Stress, 2020, 13, 100265.	4.0	3
10	The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. Schizophrenia Bulletin, 2020, 46, 1471-1481.	4.3	20
11	Brain Overexpression of Uncoupling Protein-2 (UCP2) Delays Renal Damage and Stroke Occurrence in Stroke-Prone Spontaneously Hypertensive Rats. International Journal of Molecular Sciences, 2020, 21, 4289.	4.1	12
12	Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. Brain Sciences, 2020, 10, 166.	2.3	12
13	Role of 2-Arachidonoyl-Glycerol and CB1 Receptors in Orexin-A-Mediated Prevention of Oxygenâ€“Glucose Deprivation-Induced Neuronal Injury. Cells, 2020, 9, 1507.	4.1	12
14	The Role of Macrophage Migration Inhibitory Factor in Alzheimerâ€²s Disease: Conventionally Pathogenetic or Unconventionally Protective?. Molecules, 2020, 25, 291.	3.8	31
15	N-Acetylcysteine causes analgesia in a mouse model of painful diabetic neuropathy. Molecular Pain, 2020, 16, 174480692090429.	2.1	14
16	The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 3023.	4.1	15
17	Transcriptomic Analysis Reveals Abnormal Expression of Prion Disease Gene Pathway in Brains from Patients with Autism Spectrum Disorders. Brain Sciences, 2020, 10, 200.	2.3	2
18	Acid sensing ion channel 2: A new potential player in the pathophysiology of multiple sclerosis. European Journal of Neuroscience, 2019, 49, 1233-1243.	2.6	17

#	Article	IF	Citations
19	5-HT2A receptor-dependent phosphorylation of mGlu2 receptor at Serine 843 promotes mGlu2 receptor-operated Gi/o signaling. Molecular Psychiatry, 2019, 24, 1610-1626.	7.9	17
20	Developmental abnormalities in cortical GABAergic system in mice lacking mGlu3 metabotropic glutamate receptors. FASEB Journal, 2019, 33, 14204-14220.	0.5	5
21	Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Frontiers in Psychiatry, 2019, 10, 49.	2.6	38
22	Micro-imaging of Brain Cancer Radiation Therapy Using Phase-contrast Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2018, 101, 965-984.	0.8	21
23	Synchrotron-generated microbeams induce hippocampal transections in rats. Scientific Reports, 2018, 8, 184.	3.3	7
24	Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications. Current Opinion in Pharmacology, 2018, 38, 65-71.	3.5	22
25	Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. Neuropharmacology, 2018, 128, 301-313.	4.1	79
26	In Vivo Non-radioactive Assessment of mGlu5 Receptor-Activated Polyphosphoinositide Hydrolysis in Response to Systemic Administration of a Positive Allosteric Modulator. Frontiers in Pharmacology, 2018, 9, 804.	3.5	11
27	Dickkopf-3 Causes Neuroprotection by Inducing Vascular Endothelial Growth Factor. Frontiers in Cellular Neuroscience, 2018, 12, 292.	3.7	13
28	mGlu1 Receptors Monopolize the Synaptic Control of Cerebellar Purkinje Cells by Epigenetically Down-Regulating mGlu5 Receptors. Scientific Reports, 2018, 8, 13361.	3.3	6
29	Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria. Frontiers in Neuroscience, 2018, 12, 154.	2.8	10
30	Abnormal Hippocampal Melatoninergic System: A Potential Link between Absence Epilepsy and Depression-Like Behavior in WAG/Rij Rats?. International Journal of Molecular Sciences, 2018, 19, 1973.	4.1	11
31	Mechanical Allodynia Assessment in a Murine Neuropathic Pain Model. Bio-protocol, 2018, 8, e2671.	0.4	2
32	Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacology, 2017, 112, 365-372.	4.1	63
33	The impact of metabotropic glutamate receptors into active neurodegenerative processes: A â€œdark sideâ€•in the development of new symptomatic treatments for neurologic and psychiatric disorders. Neuropharmacology, 2017, 115, 180-192.	4.1	62
34	Type-7 metabotropic glutamate receptors negatively regulate Î±1-adrenergic receptor signalling. Neuropharmacology, 2017, 113, 343-353.	4.1	4
35	Acid-sensing ion channel 1a is required for mGlu receptor dependent long-term depression in the hippocampus. Pharmacological Research, 2017, 119, 12-19.	7.1	18
36	Quantitative 3D investigation of Neuronal network in mouse spinal cord model. Scientific Reports, 2017, 7, 41054.	3.3	40

#	Article	IF	Citations
37	Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. Molecular Pain, 2017, 13, 174480691769700.	2.1	21
38	Immunoâ€pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord. British Journal of Pharmacology, 2017, 174, 4785-4796.	5.4	17
39	Alterations in the Î±₂Î´ ligand, thrombospondinâ€1, in a rat model of spontaneous absence epilepsy and in patients with idiopathic/genetic generalized epilepsies. Epilepsia, 2017, 58, 1993-2001.	5.1	8
40	Permissive role for mGlu1 metabotropic glutamate receptors in excitotoxic retinal degeneration. Neuroscience, 2017, 363, 142-149.	2.3	13
41	Rat sensorimotor cortex tolerance to parallel transections induced by synchrotron-generated X-ray microbeams. Scientific Reports, 2017, 7, 14290.	3.3	6
42	Expression of the K + /Cl â^' cotransporter, KCC2, in cerebellar Purkinje cells is regulated by group-I metabotropic glutamate receptors. Neuropharmacology, 2017, 115, 51-59.	4.1	7
43	Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway. Frontiers in Pharmacology, 2017, 8, 111.	3.5	26
44	Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?. Frontiers in Pharmacology, 2017, 8, 214.	3.5	33
45	Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator. ELife, 2017, 6, .	6.0	48
46	Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term outcome of cerebral transient focal ischemia. Molecular Brain, 2017, 10, 39.	2.6	10
47	The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget, 2017, 8, 68557-68570.	1.8	49
48	The Î±2Î´ Subunit and Absence Epilepsy: Beyond Calcium Channels?. Current Neuropharmacology, 2017, 15, 918-925.	2.9	17
49	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. Scientific Reports, 2016, 5, 17799.	3.3	91
50	Type-1, but Not Type-5, Metabotropic Glutamate Receptors are Coupled to Polyphosphoinositide Hydrolysis in the Retina. Neurochemical Research, 2016, 41, 924-932.	3.3	4
51	Antidepressant activity of fingolimod in mice. Pharmacology Research and Perspectives, 2015, 3, e00135.	2.4	42
52	Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage. Molecular Brain, 2015, 8, 66.	2.6	22
53	Monomeric ÃŸ-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons. Frontiers in Cellular Neuroscience, 2015, 9, 297.	3.7	44
54	Microradiosurgical cortical transections generated by synchrotron radiation. Physica Medica, 2015, 31, 642-646.	0.7	9

#	Article	IF	Citations
55	Simultaneous submicrometric 3D imaging of the micro-vascular network and the neuronal system in a mouse spinal cord. Scientific Reports, 2015, 5, 8514.	3.3	73
56	Metabotropic glutamate receptors as drug targets: what's new?. Current Opinion in Pharmacology, 2015, 20, 89-94.	3.5	83
57	5-HT2C serotonin receptor blockade prevents tau protein hyperphosphorylation and corrects the defect in hippocampal synaptic plasticity caused by a combination of environmental stressors in mice. Pharmacological Research, 2015, 99, 258-268.	7.1	18
58	N-Acetyl-Cysteine, a Drug that Enhances the Endogenous Activation of Group-II Metabotropic Glutamate Receptors, Inhibits Nociceptive Transmission in Humans. Molecular Pain, 2015, 11, s12990-015-0009.	2.1	29
59	Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism. Neuropharmacology, 2015, 95, 50-58.	4.1	6
60	Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2015, 74, 126-136.	4.4	41
61	New Radiosurgical Paradigms to Treat Epilepsy Using Synchrotron Radiation. , 2015, , 231-236.		0
62	Changes in mGlu5 Receptor-Dependent Synaptic Plasticity and Coupling to Homer Proteins in the Hippocampus of Ube3A Hemizygous Mice Modeling Angelman Syndrome. Journal of Neuroscience, 2014, 34, 4558-4566.	3.6	73
63	mGlu1 Receptor-Induced LTD of NMDA Receptor Transmission Selectively at Schaffer Collateral-CA1 Synapses Mediates Metaplasticity. Journal of Neuroscience, 2014, 34, 12223-12229.	3.6	16
64	Constitutively active group I mGlu receptors and PKMzeta regulate synaptic transmission in developing perirhinal cortex. Neuropharmacology, 2013, 66, 143-150.	4.1	13
65	Analgesic Effect of a Single Preoperative Dose of the Antibiotic Ceftriaxone in Humans. Journal of Pain, 2013, 14, 604-612.	1.4	28
66	Microtubule Alterations Occur Early in Experimental Parkinsonism and The Microtubule Stabilizer Epothilone D Is Neuroprotective. Scientific Reports, 2013, 3, 1837.	3.3	103
67	Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death and Differentiation, 2013, 20, 396-407.	11.2	53
68	Exposure to predator odor and resulting anxiety enhances the expression of the Î±₂Î´ subunit of voltageâ€sensitive calcium channels in the amygdala. Journal of Neurochemistry, 2013, 125, 649-656.	3.9	19
69	Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats. Neuropharmacology, 2013, 66, 339-347.	4.1	19
70	Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology, 2013, 66, 53-64.	4.1	66
71	Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacological Research, 2013, 67, 1-9.	7.1	77
72	Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Molecular Brain, 2013, 6, 48.	2.6	59

#	Article	IF	Citations
73	<scp>L</scp> -acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4804-4809.	7.1	228
74	Early Life Stress Causes Refractoriness to Haloperidol-Induced Catalepsy. Molecular Pharmacology, 2013, 84, 244-251.	2.3	9
75	Changes of peripheral TGF-Î²1 depend on monocytes-derived macrophages in Huntington disease. Molecular Brain, 2013, 6, 55.	2.6	26
76	Brain Nerve Growth Factor Unbalance Induced by Anabolic Androgenic Steroids in Rats. Medicine and Science in Sports and Exercise, 2013, 45, 29-35.	0.4	31
77	Synchrotron-Generated Microbeam Sensorimotor Cortex Transections Induce Seizure Control without Disruption of Neurological Functions. PLoS ONE, 2013, 8, e53549.	2.5	27
78	Dual Effect of 17Î²-Estradiol on NMDA-Induced Neuronal Death: Involvement of Metabotropic Glutamate Receptor 1. Endocrinology, 2012, 153, 5940-5948.	2.8	9
79	Estrogen Receptors and Type 1 Metabotropic Glutamate Receptors Are Interdependent in Protecting Cortical Neurons against Î²-Amyloid Toxicity. Molecular Pharmacology, 2012, 81, 12-20.	2.3	31
80	Cinnabarinic Acid, an Endogenous Metabolite of the Kynurenine Pathway, Activates Type 4 Metabotropic Glutamate Receptors. Molecular Pharmacology, 2012, 81, 643-656.	2.3	67
81	Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?. Neurochemistry International, 2012, 61, 559-565.	3.8	66
82	Stabbing headache in patients with autoimmune disorders. Clinical Neurology and Neurosurgery, 2012, 114, 751-753.	1.4	18
83	N-Acetyl-Cysteine Causes Analgesia by Reinforcing the Endogenous Activation of Type-2 Metabotropic Glutamate Receptors. Molecular Pain, 2012, 8, 1744-8069-8-77.	2.1	42
84	Lack or Inhibition of Dopaminergic Stimulation Induces a Development Increase of Striatal Tyrosine Hydroxylase-Positive Interneurons. PLoS ONE, 2012, 7, e44025.	2.5	13
85	Dysfunction of TGF-Î²1 signaling in Alzheimerâ€™s disease: perspectives for neuroprotection. Cell and Tissue Research, 2012, 347, 291-301.	2.9	96
86	Novel Benzo[b]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action. Journal of Medicinal Chemistry, 2011, 54, 3086-3090.	6.4	85
87	The conditioned eyeblink reflex: a potential tool for the detection of cerebellar dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1155-1161.	3.0	4
88	Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology, 2011, 60, 1281-1291.	4.1	36
89	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	3.6	64
90	TGF-Î²1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2011, 17, 237-249.	3.9	96

#	Article	IF	Citations
91	Induction of the Wnt Antagonist Dickkopf-1 Is Involved in Stress-Induced Hippocampal Damage. PLoS ONE, 2011, 6, e16447.	2.5	56
92	Metabotropic glutamate receptors in the thalamocortical network: Strategic targets for the treatment of absence epilepsy. Epilepsia, 2011, 52, 1211-1222.	5.1	43
93	Protective Role for Type 4 Metabotropic Glutamate Receptors against Ischemic Brain Damage. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1107-1118.	4.3	33
94	A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death. Neurobiology of Disease, 2011, 42, 252-264.	4.4	31
95	The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurological Sciences, 2011, 31, 283-288.	1.9	26
96	Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies Î²-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective. Molecular Pharmacology, 2011, 79, 618-626.	2.3	111
97	Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nature Medicine, 2010, 16, 897-902.	30.7	138
98	The HIV-1 Viral Protein Tat Increases Glutamate and Decreases GABA Exocytosis from Human and Mouse Neocortical Nerve Endings. Cerebral Cortex, 2010, 20, 1974-1984.	2.9	49
99	Interaction between Ephrins and mGlu5 Metabotropic Glutamate Receptors in the Induction of Long-Term Synaptic Depression in the Hippocampus. Journal of Neuroscience, 2010, 30, 2835-2843.	3.6	17
100	d-Aspartate activates mGlu receptors coupled to polyphosphoinositide hydrolysis in neonate rat brain slices. Neuroscience Letters, 2010, 478, 128-130.	2.1	32
101	Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends in Pharmacological Sciences, 2010, 31, 153-160.	8.7	80
102	Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons. PLoS ONE, 2009, 4, e6591.	2.5	48
103	Regulation of Group II Metabotropic Glutamate Receptors by G Protein-Coupled Receptor Kinases: mGlu2 Receptors Are Resistant to Homologous Desensitization. Molecular Pharmacology, 2009, 75, 991-1003.	2.3	45
104	Activation of mGlu2/3 Metabotropic Glutamate Receptors Negatively Regulates the Stimulation of Inositol Phospholipid Hydrolysis Mediated by 5-Hydroxytryptamine_{2A} Serotonin Receptors in the Frontal Cortex of Living Mice. Molecular Pharmacology, 2009, 76, 379-387.	2.3	42
105	Memantine treatment reduces the expression of the K+/Clâ^' cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABAA receptor activation in mice. Brain Research, 2009, 1265, 75-79.	2.2	20
106	Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2^{High} receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse, 2009, 63, 247-251.	1.2	27
107	Induction of the Wnt Antagonist, Dickkopf-1, Contributes to the Development of Neuronal Death in Models of Brain Focal Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 264-276.	4.3	108
108	Bilateral benign blepharoclonus. Clinical Neurology and Neurosurgery, 2009, 111, 480-481.	1.4	1

#	Article	IF	Citations
109	The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders. Neurochemical Research, 2008, 33, 2401-2406.	3.3	55
110	Metabotropic glutamate receptors regulate differentiation of embryonic stem cells into GABAergic neurons. Cell Death and Differentiation, 2008, 15, 700-707.	11.2	18
111	Enhanced expression of Harvey ras induced by serum deprivation in cultured astrocytes. Journal of Neurochemistry, 2008, 106, 551-559.	3.9	6
112	TGF-Î²1 protects against AÎ²-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiology of Disease, 2008, 30, 234-242.	4.4	74
113	GABAergic drugs become neurotoxic in cortical neurons pre-exposed to brain-derived neurotrophic factor. Molecular and Cellular Neurosciences, 2008, 37, 312-322.	2.2	7
114	Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures. Neuropharmacology, 2008, 54, 344-354.	4.1	50
115	Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis. Neuropharmacology, 2008, 54, 428-437.	4.1	23
116	Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology, 2008, 55, 525-531.	4.1	48
117	Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings. Neuropharmacology, 2008, 55, 474-482.	4.1	49
118	Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology, 2008, 55, 568-576.	4.1	40
119	Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate receptors in the cerebellum of mice developing experimental autoimmune encephalomyelitis and in autoptic cerebellar samples from patients with multiple sclerosis. Neuropharmacology, 2008, 55, 491-499.	4.1	40
120	Enhanced Tau Phosphorylation in the Hippocampus of Mice Treated with 3,4-Methylenedioxymethamphetamine (â€œEcstasyâ€). Journal of Neuroscience, 2008, 28, 3234-3245.	3.6	45
121	The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection. Journal of Neuroscience, 2007, 27, 8297-8308.	3.6	182
122	Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease. NeuroReport, 2007, 18, 1997-2000.	1.2	12
123	Metabotropic glutamate receptors: new targets for the control of tumor growth?. Trends in Pharmacological Sciences, 2007, 28, 206-213.	8.7	39
124	Pharmacological activation of mGlu2/3 metabotropic glutamate receptors protects retinal neurons against anoxic damage in the goldfish Carassius auratus. Experimental Eye Research, 2007, 84, 544-552.	2.6	12
125	Induction of the Wnt Inhibitor, Dickkopf-1, Is Associated with Neurodegeneration Related to Temporal Lobe Epilepsy. Epilepsia, 2007, 48, 694-705.	5.1	91
126	Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders. Journal of Neurochemistry, 2007, 100, 36-49.	3.9	57

#	Article	IF	Citations
127	Metabotropic glutamate receptors: Beyond the regulation of synaptic transmission. Psychoneuroendocrinology, 2007, 32, S40-S45.	2.7	29
128	Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. Journal of Neuroscience, 2006, 26, 7222-7229.	3.6	108
129	Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to Î²-amyloid. Neurobiology of Aging, 2006, 27, 606-613.	3.1	28
130	Interaction between ephrins/Eph receptors and excitatory amino acid receptors: possible relevance in the regulation of synaptic plasticity and in the pathophysiology of neuronal degeneration. Journal of Neurochemistry, 2006, 98, 1-10.	3.9	46
131	Dopamine Stimulation via Infusion in the Lateral Ventricle. Annals of the New York Academy of Sciences, 2006, 1074, 337-343.	3.8	3
132	Tic disorders: from pathophysiology to treatment. Journal of Neurology, 2006, 253, 1-15.	3.6	67
133	Protection by Apomorphine in Two Independent Models of Acute Inhibition of Oxidative Metabolism in Rodents. Clinical and Experimental Hypertension, 2006, 28, 387-394.	1.3	13
134	Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Inhibits the Growth of Medulloblastomas. Journal of Neuroscience, 2006, 26, 8388-8397.	3.6	73
135	Insulin Secretion Is Controlled by mGlu5 Metabotropic Glutamate Receptors. Molecular Pharmacology, 2006, 69, 1234-1241.	2.3	54
136	Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of Î²-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. Journal of Neurochemistry, 2005, 93, 1345-1352.	3.9	31
137	Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Reviews Neuroscience, 2005, 6, 787-798.	10.2	297
138	Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells. Cell Death and Differentiation, 2005, 12, 1124-1133.	11.2	124
139	Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against Î²-amyloid toxicity. Brain Research, 2005, 1047, 30-37.	2.2	29
140	Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. Journal of Neurology, 2005, 252, 1045-1049.	3.6	51
141	Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Required for the Development of Ischemic Neuronal Death. Journal of Neuroscience, 2005, 25, 2647-2657.	3.6	127
142	Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro-Oncology, 2005, 7, 236-245.	1.2	100
143	Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and Â-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3413-3418.	7.1	480
144	Endogenous activation of mGlu5 metabotropic glutamate receptors supports self-renewal of cultured mouse embryonic stem cells. Neuropharmacology, 2005, 49, 196-205.	4.1	51

#	Article	IF	Citations
145	The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spikeâ€“wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology, 2005, 49, 89-103.	4.1	53
146	Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. Journal of Neurochemistry, 2004, 88, 114-123.	3.9	110
147	Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice. Journal of Neuroscience, 2004, 24, 828-835.	3.6	113
148	PHCCC, a Specific Enhancer of Type 4 Metabotropic Glutamate Receptors, Reduces Proliferation and Promotes Differentiation of Cerebellar Granule Cell Neuroprecursors. Journal of Neuroscience, 2004, 24, 10343-10352.	3.6	65
149	Mouse hepatocytes lacking mGlu5 metabotropic glutamate receptors are less sensitive to hypoxic damage. European Journal of Pharmacology, 2004, 497, 25-27.	3.5	19
150	Similarities between Methamphetamine Toxicity and Proteasome Inhibition. Annals of the New York Academy of Sciences, 2004, 1025, 162-170.	3.8	45
151	Effects of Repeated Low Doses of MDMA on EEG Activity and Fluoro-Jade B Histochemistry. Annals of the New York Academy of Sciences, 2004, 1025, 181-188.	3.8	6
152	Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. Journal of Neurochemistry, 2004, 86, 413-421.	3.9	23
153	Double-knockout mice for Â- and Â-synucleins: Effect on synaptic functions. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14966-14971.	7.1	392
154	Metabotropic Glutamate Receptors and Neurodegeneration. , 2004, , 79-102.		7
155	Optimizing levodopa pharmacokinetics in Parkinson?s disease: the role of COMT inhibitor. Neurological Sciences, 2003, 24, 217-218.	1.9	39
156	Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. Journal of Neurochemistry, 2003, 84, 1288-1295.	3.9	78
157	Selective blockade of mGlu5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice. Journal of Hepatology, 2003, 38, 179-187.	3.7	29
158	Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamicâ€“pituitaryâ€“adrenocortical axis. Neuropharmacology, 2003, 44, 555-561.	4.1	53
159	Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology, 2003, 45, 155-166.	4.1	60
160	(â^')-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology, 2003, 45, 895-906.	4.1	206
161	Group II Metabotropic Glutamate Receptors Regulate the Vulnerability to Hypoxic Brain Damage. Journal of Neuroscience, 2003, 23, 6023-6029.	3.6	30
162	Neuroprotective Activity of Metabotropic Glutamate Receptor Ligands. Advances in Experimental Medicine and Biology, 2003, 513, 197-223.	1.6	75

#	Article	IF	Citations
163	Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain, 2002, 125, 2635-2645.	7.6	76
164	Erratic expression of DNA polymerases by Î²â€amyloid causes neuronal death. FASEB Journal, 2002, 16, 2006-2008.	0.5	55
165	Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity. Journal of Neuroscience, 2002, 22, 2135-2141.	3.6	134
166	Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures. Journal of Neuroscience, 2002, 22, 5403-5411.	3.6	79
167	Some Metabotropic Glutamate Receptor Ligands Reduce Kynurenate Synthesis in Rats by Intracellular Inhibition of Kynurenine Aminotransferase II. Journal of Neurochemistry, 2002, 75, 2051-2060.	3.9	19
168	Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission. Molecular and Cellular Neurosciences, 2001, 17, 1071-1083.	2.2	92
169	An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. European Journal of Neuroscience, 2001, 13, 1469-1478.	2.6	62
170	Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1013-1033.	4.3	297
171	Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Research, 2001, 898, 27-35.	2.2	40
172	Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. International Journal of Pharmaceutics, 2000, 202, 79-88.	5.2	50
173	Expression of metabotropic glutamate receptors in murine thymocytes and thymic stromal cells. Journal of Neuroimmunology, 2000, 109, 112-120.	2.3	74
174	Time-course and doseâ€“response study on the effects of chronic l-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Research, 2000, 887, 110-117.	2.2	38
175	Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. European Journal of Pharmacology, 1998, 356, 271-274.	3.5	44
176	Chapter 14 Metabotropic glutamate receptors and neurodegeneration. Progress in Brain Research, 1998, 116, 209-221.	1.4	26
177	In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neuroscience Letters, 1997, 229, 161-164.	2.1	150
178	Activation of Metabotropic Glutamate Receptors Prevents Neuronal Apoptosis in Culture. Journal of Neurochemistry, 1995, 64, 101-108.	3.9	109
179	Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. European Journal of Pharmacology, 1994, 256, 109-112.	3.5	109
180	Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neuroscience Letters, 1994, 178, 193-196.	2.1	21

#	Article	IF	Citations
181	Synergic action of L-acetylcarnitine and L-methylfolate in Mouse Models of Stress-Related Disorders and Human iPSC-Derived Dopaminergic Neurons. Frontiers in Pharmacology, 0, 13, .	3.5	0